^
    Back
    Association details:
    Biomarker:MYC expression + BCL2 expression + BCL6 expression
    Cancer:Lymphoma
    Regimen:R-CHOP (cyclophosphamide + doxorubicin hydrochloride + prednisone + Rituxan (rituximab) + vincristine)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Zhongguo Shi Yan Xue Ye Xue Za Zhi
    Title:

    The Effect of Bcl-6 Expression on the Prognosis of Newly Treated Double-Expressing Lymphoma Treated with R-CHOP Regimen

    Published date:
    12/01/2021
    Excerpt:
    152 double-expression lymphoma patients (myc+/bcl-2+) treated in the Oncology Department of the First Affiliated Hospital of Zhengzhou University from September 2016 to June 2020 were selected....152 double-expression lymphoma patients (myc+/bcl-2+) treated in the Oncology Department of the First Affiliated Hospital of Zhengzhou University from September 2016 to June 2020 were selected.
    DOI:
    10.19746/j.cnki.issn.1009-2137.2021.06.018